These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8067747)

  • 1. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.
    Onyeji CO; Nicolau DP; Nightingale CH; Quintiliani R
    Antimicrob Agents Chemother; 1994 May; 38(5):1112-7. PubMed ID: 8067747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis.
    McCabe R; Rumans L; Perrotta R; Mogabgab W
    J Chemother; 1993 Apr; 5(2):124-32. PubMed ID: 8515295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.
    van Ogtrop ML; Andes D; Stamstad TJ; Conklin B; Weiss WJ; Craig WA; Vesga O
    Antimicrob Agents Chemother; 2000 Apr; 44(4):943-9. PubMed ID: 10722495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections.
    Kammer RB; Ress R
    Diagn Microbiol Infect Dis; 1991; 14(1):101-5. PubMed ID: 2013204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo efficacy of cefcanel daloxate in comparison with cefaclor.
    Magni L; Lionell C
    Scand J Infect Dis Suppl; 1990; 74():185-9. PubMed ID: 2097707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multinational multicenter controlled trial comparing ceftibuten with cefaclor for the treatment of acute otitis media. Members of the Ceftibuten Otitis Media International Study Group.
    Blumer JL; Mclinn SE; Deabate CA; Kafetzis DA; Perrotta RJ; Salgado O
    Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S115-20. PubMed ID: 7567311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftibuten versus cefaclor for the treatment of bronchitis.
    Chirurgi VA; Edelstein H; Oster SE; Karp R; Cassano KB; Aiken S; Krumpe P; McCabe RE
    J Antimicrob Chemother; 1991 Oct; 28(4):577-80. PubMed ID: 1761452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
    Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefaclor into the millennium.
    Brumfitt W; Hamilton-Miller JM
    J Chemother; 1999 Jun; 11(3):163-78. PubMed ID: 10435677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
    Nix DE; Symonds WT; Hyatt JM; Wilton JH; Teal MA; Reidenberg P; Affrime MB
    Pharmacotherapy; 1997; 17(1):121-5. PubMed ID: 9017772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.
    Jones RN; Pfaller MA; Jacobs MR; Appelbaum PC; Fuchs PC
    Diagn Microbiol Infect Dis; 2001; 41(1-2):1-14. PubMed ID: 11687308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin.
    Tomatsu K; Ando S; Masuyoshi S; Kondo S; Hirano M; Miyaki T; Kawaguchi H
    J Antibiot (Tokyo); 1987 Aug; 40(8):1175-83. PubMed ID: 3500158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in-vitro activity of ceftibuten against 475 clinical isolates of gram-negative bacilli, compared with cefuroxime and cefadroxil.
    Bragman SG; Casewell MW
    J Antimicrob Chemother; 1990 Feb; 25(2):221-6. PubMed ID: 2329100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.
    Wiseman LR; Benfield P
    Drugs; 1993 Feb; 45(2):295-317. PubMed ID: 7681376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis.
    Cazzola M; Di Perna F; Boveri B; Di Marco F; Diamare F; Centanni S
    J Chemother; 2000 Jun; 12(3):216-22. PubMed ID: 10877516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
    Kays MB
    Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of respiratory and urinary pathogens to ceftibuten and other comparative drugs: results of an Italian multicenter survey. The Italian Ceftibuten Study Group.
    Schito GC; Nicoletti G
    J Chemother; 1994 Apr; 6(2):92-8. PubMed ID: 8077991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.